AINewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Achieves Key Milestone in Global Trial for Never-Smoker Lung Cancer
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. The company recently “completed targeted patient enrollment in Japan for its ongoing Phase 2 HARMONIC(TM) clinical trial evaluating investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (‘NSCLC’) patients,” reads a recent article. “Completing our targeted enrollment in Japan ahead of schedule demonstrates excellent execution of our international expansion strategy and validates our decision to focus on regions where never-smoker NSCLC has the highest prevalence,” Lantern Pharma CEO and President Panna Sharma was quoted as saying. “This achievement builds…